{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:28:11Z","timestamp":1793665691827,"version":"4.5.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Current meta-analysis was performed to systematically evaluate the survival outcomes and tumor response of hepatic arterial infusion chemotherapy (HAIC) for unresectable intrahepatic cholangiocarcinoma (iCCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, Medline (Ovid), Scopus, Embase, Web of Science, and the Cochrane Library databases. The primary outcomes were overall survival and progression-free survival (PFS) expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). The secondary outcomes were response rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>\n                      Nine retrospective cohort studies with 1259 patients were identified. The overall analysis demonstrated a significant reduction in mortality following HAIC (HR\u00a0=\u00a00.49, 95% CI: 0.35\u20130.62;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a065.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.003). All subgroup analyses demonstrated statistically significant HRs, and subgroup studies focusing on extrahepatic metastasis demonstrated minimal heterogeneity (\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.792 and\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a00,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.508). Six studies reported the median PFS and provided Kaplan\u2013Meier curves of both groups. The overall analysis demonstrated a significant reduction in disease progression following HAIC (HR\u00a0=\u00a00.56, 95% CI: 0.37\u20130.75;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a054.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.054). In six studies that reported objective response rate (ORR), we found higher ORR in the HAIC group than that in the systemic chemotherapy (SC) group (RR 2.26, 95% CI: 1.78\u20132.88;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a025.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.244). In six studies that reported disease control rate (DCR), we found higher DCR in the HAIC group than that in the SC group (RR 1.27, 95% CI: 1.07\u20131.50;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u00a0=\u00a068.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This meta-analysis demonstrated that HAIC is associated with a significantly reduced risk of mortality and disease progression in patients with unresectable iCCA. HAIC is also associated with higher tumor response rates compared to SC in unresectable iCCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004974","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T19:00:18Z","timestamp":1771441218000},"page":"12287-12296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic arterial infusion chemotherapy versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3177-6245","authenticated-orcid":false,"given":"Ao-Yao","family":"Xi","sequence":"first","affiliation":[{"name":"Department of General Surgery, West China Emei Hospital, Sichuan University, Emeishan, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"The first Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Xu","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6126-6611","authenticated-orcid":false,"given":"Wen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biliary Tract Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China"},{"name":"West China School of Nursing, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"R1-20261102","doi-asserted-by":"crossref","first-page":"2168\u201379","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"R2-20261102","doi-asserted-by":"crossref","first-page":"587\u201399","DOI":"10.1016\/j.soc.2019.06.002","article-title":"Intrahepatic cholangiocarcinoma","volume":"28","author":"El-Diwany","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"R3-20261102","doi-asserted-by":"crossref","first-page":"1440\u201353","DOI":"10.1097\/JS9.0000000000002134","article-title":"Anatomic versus nonanatomic resection for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"111","author":"Jiang","year":"2025","journal-title":"Int J Surg"},{"key":"R4-20261102","doi-asserted-by":"crossref","first-page":"1354\u201362","DOI":"10.1002\/cncr.30488","article-title":"Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients","volume":"123","author":"Yamashita","year":"2017","journal-title":"Cancer"},{"key":"R5-20261102","doi-asserted-by":"crossref","first-page":"95\u2013111","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20261102","doi-asserted-by":"crossref","first-page":"1273\u201381","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20261102","doi-asserted-by":"crossref","first-page":"1260191","DOI":"10.3389\/fimmu.2024.1260191","article-title":"Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"R8-20261102","first-page":"3784\u201392","article-title":"A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2019-deoxyuridine and 5-fluorouracil","volume":"38","author":"Ensminger","year":"1978","journal-title":"Cancer Res"},{"key":"R9-20261102","doi-asserted-by":"crossref","first-page":"1836\u201340","DOI":"10.1200\/JCO.1987.5.11.1836","article-title":"Tumor and liver drug uptake following hepatic artery and portal vein infusion","volume":"5","author":"Sigurdson","year":"1987","journal-title":"J Clin Oncol"},{"key":"R10-20261102","first-page":"969\u201377","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"key":"R11-20261102","first-page":"5528\u201338","article-title":"Hepatic arterial infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"29","author":"Holster","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R12-20261102","article-title":"Transparency in the Reporting of Artificial Intelligence \u2013 the TITAN Guideline","volume":"10:100082","author":"Riaz","year":"2025","journal-title":"Prem J Sci"},{"key":"R13-20261102","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20261102","first-page":"2025. doi: 10.70389\/PJS.100081","article-title":"Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery (STROCSS) guideline: an update for the age of artificial intelligence","author":"Riaz","journal-title":"Prem J Sci"},{"key":"R15-20261102","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Bmj"},{"key":"R16-20261102","doi-asserted-by":"crossref","first-page":"603\u201305","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R17-20261102","doi-asserted-by":"crossref","first-page":"758\u201367","DOI":"10.1016\/S1470-2045(18)30188-8","article-title":"Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"19","author":"Yamada","year":"2018","journal-title":"Lancet Oncol"},{"key":"R18-20261102","doi-asserted-by":"crossref","first-page":"228\u201347","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R19-20261102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13643-025-02752-z","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance","volume":"14","author":"Tierney","year":"2025","journal-title":"Syst Rev"},{"key":"R20-20261102","doi-asserted-by":"crossref","first-page":"328\u201345","DOI":"10.1002\/cpt.3312","article-title":"Risk versus benefit of tyrosine kinase inhibitors for hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials","volume":"116","author":"Payo-Seraf\u00edn","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"R21-20261102","doi-asserted-by":"crossref","first-page":"4342\u201355","DOI":"10.1097\/JS9.0000000000001403","article-title":"Prognostic factors for resected cases with gallbladder carcinoma: a systematic review and meta-analysis","volume":"110","author":"Lv","year":"2024","journal-title":"Int J Surg"},{"key":"R22-20261102","doi-asserted-by":"crossref","first-page":"1539\u201358","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R23-20261102","doi-asserted-by":"crossref","first-page":"629\u201334","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R24-20261102","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"Bmj"},{"key":"R25-20261102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/curroncol32020087","article-title":"The efficacy and safety of hepatic artery infusion chemotherapy combined with lenvatinib and programmed death (PD)-1 inhibitors for unresectable intrahepatic cholangiocarcinoma: a retrospective study","volume":"32","author":"Cai","year":"2025","journal-title":"Curr Oncol"},{"key":"R26-20261102","doi-asserted-by":"crossref","first-page":"4922\u201334","DOI":"10.62347\/HVOF5644","article-title":"Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma","volume":"14","author":"Zhao","year":"2024","journal-title":"Am J Cancer Res"},{"key":"R27-20261102","doi-asserted-by":"crossref","first-page":"23961","DOI":"10.1038\/s41598-024-75102-z","article-title":"Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"key":"R28-20261102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00432-024-05795-2","article-title":"First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma","volume":"150","author":"Lin","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"R29-20261102","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jvir.2023.11.015","article-title":"Systemic chemotherapy with or without hepatic arterial infusion chemotherapy for intrahepatic cholangiocarcinoma with extrahepatic oligometastasis: a propensity score\u2013matched analysis","volume":"35","author":"Li","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"R30-20261102","doi-asserted-by":"crossref","first-page":"115\u201324","DOI":"10.1245\/s10434-023-14488-y","article-title":"Gemcitabine with cisplatin versus hepatic arterial infusion pump chemotherapy for liver-confined unresectable intrahepatic cholangiocarcinoma","volume":"31","author":"Franssen","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R31-20261102","doi-asserted-by":"crossref","first-page":"e0266707","DOI":"10.1371\/journal.pone.0266707","article-title":"Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma","volume":"17","author":"Ishii","year":"2022","journal-title":"PLoS One"},{"key":"R32-20261102","first-page":"4101\u201308","article-title":"Intrahepatic cholangiocarcinoma with lymph node metastasis: treatment-related outcomes and the role of tumor genomics in patient selection","volume":"27","author":"Jolissaint","journal-title":"Clin Cancer Res"},{"key":"R33-20261102","doi-asserted-by":"crossref","first-page":"758\u201365","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"key":"R34-20261102","doi-asserted-by":"crossref","first-page":"2675\u201383","DOI":"10.1245\/s10434-014-3649-y","article-title":"Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials","volume":"21","author":"Konstantinidis","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R35-20261102","doi-asserted-by":"crossref","first-page":"83\u201390","DOI":"10.1245\/s10434-017-6110-1","article-title":"Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies","volume":"25","author":"Wright","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R36-20261102","doi-asserted-by":"crossref","first-page":"84\u201396","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann Surg"},{"key":"R37-20261102","doi-asserted-by":"crossref","first-page":"300\u201309","DOI":"10.1159\/000512967","article-title":"Combination of HAI-FUDR and systemic gemcitabine and cisplatin in unresectable cholangiocarcinoma: a dose finding single center study","volume":"99","author":"Pietge","year":"2021","journal-title":"Oncology"},{"key":"R38-20261102","doi-asserted-by":"crossref","first-page":"60\u201367","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol"},{"key":"R39-20261102","doi-asserted-by":"crossref","first-page":"1589\u201395","DOI":"10.1093\/annonc\/mdp029","article-title":"Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival","volume":"20","author":"Jarnagin","year":"2009","journal-title":"Ann Oncol"},{"key":"R40-20261102","doi-asserted-by":"crossref","first-page":"153\u201359","DOI":"10.1159\/000324704","article-title":"Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?","volume":"80","author":"Kemeny","year":"2011","journal-title":"Oncology"},{"key":"R41-20261102","first-page":"3455\u201363","article-title":"Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study","volume":"12","author":"Zhang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"R42-20261102","doi-asserted-by":"crossref","first-page":"1552\u201357","DOI":"10.1097\/JS9.0000000000002013","article-title":"Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study","volume":"111","author":"Zheng","year":"2025","journal-title":"Int J Surg"},{"key":"R43-20261102","first-page":"209\u201325","article-title":"Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis","volume":"16","author":"Hu","year":"2025","journal-title":"J Gastrointestinal Oncol"},{"key":"R44-20261102","doi-asserted-by":"crossref","first-page":"1234342","DOI":"10.3389\/fphar.2023.1234342","article-title":"Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma","volume":"14:","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"R45-20261102","doi-asserted-by":"crossref","first-page":"120\u201327","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis","volume":"41","author":"Al-Adra","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"R46-20261102","first-page":"5462\u201373","article-title":"Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin","volume":"29","author":"Martin","year":"2022","journal-title":"Ann Surg Oncol"}],"updated-by":[{"DOI":"10.1097\/js9.0000000000005647","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000004974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:02:01Z","timestamp":1793664121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/JS9.0000000000004974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004974","relation":{},"ISSN":["1743-9159","1743-9191"],"issn-type":[{"value":"1743-9159","type":"electronic"},{"value":"1743-9191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"2025-06-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}